Back to results
US 11,446,398 B2Granted
Regulated biocircuit systems
AssigneeObsidian Therapeutics, Inc.
InventorsPeter Barrett, Michael N. Gladstone, Tariq A. Kassum, Vipin Suri, Dan Jun Li, Dexue Sun, Brian Dolinski
Life of this patent
Estimating the term…
Abstract
The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.
Claims7
A regulatable human T cell engineered to express an effector module or a population of regulatable human T cells engineered to express the effector module, wherein the effector module comprises:
- a first component and a second component,
- wherein said first component is a stimulus response element (SRE) comprising an FK506 binding protein (FKBP) destabilizing domain (DD), wherein the FKBP DD comprises mutations F36V and L106P and comprises SEQ ID NO:
- 213274 or comprises mutation E31G, F36V, R71G, and K105E and comprises SEQ ID NO:
- 213297 and
- wherein said second component is a chimeric antigen receptor that recognizes a C19 antigen, and wherein said effector module is responsive to at least one stimulus.
2 more elements
Dependencies are inferred from the claim text.